E2F2 Rabbit Polyclonal Antibody

CAT#: TA322797

Anti-E2F2 Rabbit Polyclonal Antibody

Product Images

Gel: 12+15%SDS-PAGE Lysate: 40 μg Lane: A549 cells Primary antibody: TA322797 (E2F2 Antibody) at dilution 1/600 Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution Exposure time: 10 minutes

Specifications

Product Data

• Applications: WB
• Recommended Dilution: WB: 500-2000
  WB positive control: A549 cells
• Reactivities: Human
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: Full length fusion protein
• Formulation: PBS pH7.3, 0.05% NaN3, 50% glycerol
• Concentration: lot specific
• Purification: Antigen affinity purification
• Conjugation: Unconjugated
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Predicted Protein Size: 48 kDa
• Gene Name: E2F transcription factor 2
• Database Link:
  NP_004082
  Entrez Gene 1870 Human
  UniProt ID Q14209
• Background: The protein encoded by this gene is a member of the E2F family of transcription factors. The E2F family plays a crucial role in the control of cell cycle and action of tumor suppressor proteins and is also a target of the transforming proteins of small DNA tumor viruses. The E2F proteins contain several evolutionally conserved domains found in most members of the family. These domains include a DNA binding domain; a dimerization domain which determines interaction with the differentiation regulated transcription factor proteins (DP); a transactivation domain enriched in acidic amino acids; and a tumor suppressor protein association domain which is embedded within the transactivation domain. This protein and another 2 members; E2F1 and E2F3; have an additional cyclin binding domain. This protein binds specifically to retinoblastoma protein pRB in a cell-cycle dependent manner; and it exhibits overall 46% amino acid identity to E2F1.?
• Synonyms: E2F-2

Reference Data

• Protein Families: Druggable Genome, Transcription Factors
• Protein Pathways: Bladder cancer, Cell cycle, Chronic myeloid leukemia, Glioma, Melanoma, Non-small cell lung cancer, Pancreatic cancer, Pathways in cancer, Prostate cancer, Small cell lung cancer